Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was down 4.2% on Thursday . The company traded as low as $4.52 and last traded at $4.52, with a volume of 1,275,372 shares trading hands. The stock had previously closed at $4.72.

A number of equities research analysts have recently commented on KERX shares. Raymond James Financial Inc. upped their target price on shares of Keryx Biopharmaceuticals from $7.00 to $10.00 and gave the company an “outperform” rating in a report on Tuesday, August 2nd. Maxim Group cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 1st. Ladenburg Thalmann upped their target price on shares of Keryx Biopharmaceuticals from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 2nd. Cowen and Company reaffirmed a “neutral” rating on shares of Keryx Biopharmaceuticals in a report on Wednesday, August 3rd. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $13.00 target price on shares of Keryx Biopharmaceuticals in a report on Tuesday, May 17th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company. Keryx Biopharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $7.75.

The company’s market cap is $490.29 million. The firm has a 50-day moving average of $5.77 and a 200 day moving average of $5.30.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.14. The firm had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. Keryx Biopharmaceuticals’s quarterly revenue was up 272.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.26) earnings per share. Equities research analysts anticipate that Keryx Biopharmaceuticals Inc. will post ($1.23) EPS for the current fiscal year.

In other news, CFO Scott A. Holmes sold 4,935 shares of Keryx Biopharmaceuticals stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $7.36, for a total value of $36,321.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

An institutional investor recently raised its position in Keryx Biopharmaceuticals stock. Schwab Charles Investment Management Inc. boosted its stake in Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 375,655 shares of the biopharmaceutical company’s stock after buying an additional 13,405 shares during the period. Schwab Charles Investment Management Inc. owned 0.36% of Keryx Biopharmaceuticals worth $1,898,000 as of its most recent SEC filing.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.